Rinath Jeselsohn

Rinath Jeselsohn

UNVERIFIED PROFILE

Are you Rinath Jeselsohn?   Register this Author

Register author
Rinath Jeselsohn

Rinath Jeselsohn

Publications by authors named "Rinath Jeselsohn"

Are you Rinath Jeselsohn?   Register this Author

29Publications

927Reads

47Profile Views

Estrogen receptor signaling is reprogrammed during breast tumorigenesis.

Proc Natl Acad Sci U S A 2019 Jun 20;116(23):11437-11443. Epub 2019 May 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1819155116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561257PMC
June 2019

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.

Cancer Cell 2018 12 21;34(6):939-953.e9. Epub 2018 Nov 21.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Eli and Edythe L Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Ludwig Center at Harvard, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183048
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310147PMC
December 2018

Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.

Cancer Discov 2018 11;8(11):1352-1354

Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-1084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217858PMC
November 2018

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

Cancer Cell 2018 02;33(2):173-186.e5

Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02210, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02210, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813700PMC
February 2018

Are We Ready to Use ESR1 Mutations in Clinical Practice?

Authors:
Rinath Jeselsohn

Breast Care (Basel) 2017 Oct 25;12(5):309-313. Epub 2017 Oct 25.

Breast Oncology Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/481428
Publisher Site
http://dx.doi.org/10.1159/000481428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704725PMC
October 2017

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Curr Oncol Rep 2017 May;19(5):35

Smith Breast Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0591-8DOI Listing
May 2017

Immune Complex-Mediated Proliferative Glomerulonephritis Induced by Paclitaxel Treatment.

J Oncol Pract 2016 12 15;12(12):1272-1274. Epub 2016 Nov 15.

Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Southern Arizona Veterans Affairs Health Care System; and University of Arizona College of Medicine, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.016956DOI Listing
December 2016

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Proc Natl Acad Sci U S A 2016 10 6;113(43):E6600-E6609. Epub 2016 Oct 6.

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1612835113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087040PMC
October 2016

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Mol Cancer Res 2016 05 10;14(5):470-81. Epub 2016 Mar 10.

Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. Department of Medicine, Baylor College of Medicine, Houston, Texas. Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-15-0423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867274PMC
May 2016

How drug resistance takes shape.

Elife 2016 03 24;5. Epub 2016 Mar 24.

Center for Functional Cancer Epigenetics and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7554/eLife.14973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821798PMC
March 2016

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Nat Rev Clin Oncol 2015 Oct 30;12(10):573-83. Epub 2015 Jun 30.

Lester &Sue Smith Breast Center and Dan L. Duncan Cancer Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2015.117
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2015.117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911210PMC
October 2015

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Cancer Res 2013 Dec 11;73(23):6856-64. Epub 2013 Nov 11.

Authors' Affiliations: Department of Oncology, Tel Aviv Sourasky Medical Center; Sackler Faculty of Medicine; The Bioinformatics Unit, Goerge S. Wise Faculty of Life Sciences, Tel Aviv University; Assuta Medical Center, Tel Aviv; Kaplan Medical Center, Rehovot; Oncotest-Teva Pharmaceutical Industries; Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Foundation Medicine, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1197DOI Listing
December 2013

PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.

Cancer Cell 2013 Jun;23(6):753-67

Division of Molecular and Cellular Oncology, Department of Medical Oncology, and Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2013.04.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711136PMC
June 2013

Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium.

Cancer Res 2012 Dec 4;72(24):6477-89. Epub 2012 Oct 4.

Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-4139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525807PMC
December 2012